New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
04:55 EDTNVDQ, NVDQ, NVDQ, MMSI, MMSI, MMSI, TEAR, TEAR, TEAR, ABAX, ABAX, ABAX, ELGX, ELGX, ELGX, VASC, VASC, VASCLazard to hold a conference
6th Annual MedTech, Diagnostics & Healthcare IT Snowbird Conference is being held in Snowbird, Utah on March 18-20.
News For NVDQ;MMSI;TEAR;ABAX;ELGX;VASC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
08:03 EDTVASCVascular Solutions receives FDA clearance for Gel-Block 10x embolization product
Subscribe for More Information
07:41 EDTABAXAbaxis price target raised to $64 from $60 at Canaccord
Subscribe for More Information
November 21, 2014
08:06 EDTABAXAbaxis acquires U.K.-based distribution organization
Subscribe for More Information
07:16 EDTELGXEndologix trial results 'highly encouraging,' says Stifel
Subscribe for More Information
November 20, 2014
07:13 EDTNVDQ, ELGXCanaccord to hold a forum
Subscribe for More Information
November 19, 2014
10:15 EDTMMSIMerit Medical management to meet with Sidoti
Subscribe for More Information
November 18, 2014
11:00 EDTELGXEndologix to host investor meeting
Subscribe for More Information
07:11 EDTELGXEndologix completes patient enrollment in Nellix EVAS FORWARD-IDE clinical trial
Endologix announced that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms, or AAA. Primary endpoint analysis results at one-year and beyond will be used to support the company's premarket approval, or PMA, application to the FDA for the Nellix EVAS System. The EVAS FORWARD-IDE clinical trial enrolled 179 patients at 29 centers in the U.S. and Europe. Enrollment under an extended investigation phase is anticipated to begin shortly and will continue during the pivotal trial follow-up period and PMA preparation/review process. Based on current assumptions and timelines, the company anticipates FDA approval of the Nellix System in the U.S. before the end of 2016.
November 14, 2014
16:21 EDTVASCOn The Fly: Closing Wrap
Subscribe for More Information
15:20 EDTNVDQNovadaq to host investor day
Subscribe for More Information
12:58 EDTVASCOn The Fly: Midday Wrap
Subscribe for More Information
08:34 EDTVASCVascular Solutions weakness a buying opportunity, says Canaccord
Subscribe for More Information
November 13, 2014
16:31 EDTVASCVascular Solutions issues statement regarding grand jury indictment
Subscribe for More Information
16:29 EDTVASCVascular Solutions announces $20M share repurchase program
Subscribe for More Information
November 12, 2014
06:15 EDTNVDQJanus Capital reports 10.6% passive stake in Novadaq
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use